Myotonic Dystrophy - Pipeline Insight, 2026

This “Myotonic Dystrophy - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myotonic Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Myotonic Dystrophy: Understanding

Myotonic Dystrophy: Overview

Myotonic dystrophy is a chronic, progressive, autosomal dominant disorder characterized by muscle weakness and myotonia, which refers to the delayed relaxation of muscles after contraction. There are two major forms recognized based on clinical and molecular presentation: Myotonic dystrophy type I (DM1), known as Steinert disease, and myotonic dystrophy type II (DM2), or proximal myotonic myopathy which is a milder variety of DMI. These are progressive, multisystem genetic disorders. Clinical presentation is diverse and can range from asymptomatic electrical myotonia to severe weakness and disability, including cardiac conduction defects, infertility, cataracts, and insulin resistance.

This is an inherited disorder passed from parent to child, caused by mutations in specific genes. Myotonic dystrophy type 1 results from mutations in the DMPK gene, while type 2 is caused by mutations in the CNBP gene. In both types, the underlying defect involves abnormal repetition of a DNA segment, creating an unstable region within the gene. The extent of these repeated sequences is directly associated with disease severity, with larger expansions leading to more pronounced manifestations. These abnormal DNA repeats produce excess messenger RNA, which is toxic to cells and disrupts the normal production of multiple proteins, ultimately contributing to the multisystem nature of the disorder.

Myotonic dystrophy is associated with a wide range of symptoms that primarily affect the muscles but can also involve multiple body systems. The main symptoms include progressive muscle weakness, muscle wasting (atrophy), and myotonia, which is the inability to relax muscles after contraction. In addition, the condition can affect other organs such as the heart, eyes, and endocrine system, leading to complications like cardiac conduction abnormalities, cataracts, and metabolic disturbances. The severity and progression of symptoms vary depending on the type of myotonic dystrophy and the individual.

The disease currently has no definitive cure, and treatment is mainly focused on managing symptoms and associated complications. This may involve the use of medications to control myotonia, physical therapy to maintain muscle strength and function, and assistive devices when needed. Additionally, complications such as cardiac abnormalities, respiratory issues, and metabolic disturbances are treated individually to improve quality of life. Overall, treatment is aimed at slowing disease progression, reducing complications, and enhancing patient well-being rather than addressing the underlying genetic cause.

"Myotonic Dystrophy- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myotonic Dystrophy pipeline landscape is provided which includes the disease overview and Myotonic Dystrophy treatment guidelines. The assessment part of the report embraces, in depth Myotonic Dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myotonic Dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myotonic Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Myotonic Dystrophy.

Myotonic Dystrophy Emerging Drugs Chapters

This segment of the Myotonic Dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myotonic Dystrophy Emerging Drugs

• Del-desiran (AOC 1001): Novartis AG

Del-desiran, utilizing Avidity's AOC platform technology, is designed to address the underlying genetic cause of DM1 by reducing levels of toxic DMPK mRNA. Del-desiran consists of a proprietary monoclonal antibody that binds to transferrin receptor 1 (TfR1) and is conjugated to a siRNA that targets DMPK mRNA. Del-desiran has received Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA) and Orphan designation by the European Medicines Agency (EMA). Del-desiran was also the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. This drug was developed by Avidity Biosciences which has been fully acquired by Novartis AG. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Myotonic Dystrophy.

• ARO-DM1: Arrowhead Pharmaceuticals, Inc.

ARO-DM1 is an RNA interference (RNAi) conjugate designed to specifically silence DMPK mRNA in skeletal muscle and the silencing of aberrantly transcribed DMPK mRNA using ARO-DM1 may halt CUGexp-related spliceopathies in patients with DM1 leading to improved muscle strength and function. This drug belongs to a class of medicines called RNA therapeutics. Preclinical data shows ARO-DM1 achieved greater than 80% silencing of DMPK in skeletal muscle, which was maintained for longer than 85 days. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Myotonic Dystrophy.

• ATX-01: Arthex Biotech

ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b(miR-23b), which is involved in the pathogenesis of DM1. It has been demonstrated, in human DM1 myoblast cell lines and in two murine models, that ATX-01 has a unique, dual mechanism of action which reduces toxic DMPK mRNA and increases MBNL protein production. ATX-01 was discovered through ARTHEx’s in-house discovery engine, which was built to identify, design and optimize novel gene expression modulators and ensure their preferential delivery to target tissues affected by the disease. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Myotonic Dystrophy.

• SAR446268: Sanofi

SAR446268 employs a vectorized RNA interference (RNAi) approach to silence DMPK expression through a single administration. By reducing DMPK transcripts, the gene therapy aims to eliminate the abnormal and toxic RNA foci responsible for splicing defects in muscle tissue, thereby restoring normal splicing and improving muscular function. This approach has the potential to address key symptoms of the disease, including progressive muscle weakness, difficulty relaxing muscles (myotonia), and effects on multiple body systems including heart, lungs, and endocrine functions. The US Food and Drug Administration (FDA) has granted fast track designation to SAR446268 in September 2025. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Myotonic Dystrophy.

Further product details are provided in the report……..

Myotonic Dystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Myotonic Dystrophy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myotonic Dystrophy

There are approx. 20+ key companies which are developing the therapies Myotonic Dystrophy. The companies which have their Myotonic Dystrophy drug candidates in the most advanced stage, i.e. Phase III include, Novartis AG, and others.

Phases

The report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Myotonic Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myotonic Dystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myotonic Dystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myotonic Dystrophy drugs.

Myotonic Dystrophy Report Insights

• Myotonic Dystrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Myotonic Dystrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Myotonic Dystrophy drugs?
• How many Myotonic Dystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myotonic Dystrophy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myotonic Dystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myotonic Dystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis AG
• Arrowhead Pharmaceuticals, Inc.
• Arthex Biotech
• Sanofi
• DYNE therapeutics
• PepGen Inc.
• Vertex Pharmaceuticals Incorporated
• AMO Pharma
• Harmony Biosciences
• Ionis Pharmaceuticals
• Sarepta Therapeutics, Inc.
• Juvena Therapeutics Inc.

Key Products

• Del-desiran (AOC 1001)
• ARO-DM1
• ATX-01
• SAR446268
• DYNE-101
• PGN-EDODM1
• VX-670
• Tideglusib (AMO-02)
• Pitolisant
• IONIS-877864
• SRP-1003
• JUV-161

This product will be delivered within 1-3 business days.